Media coverage about AxoGen (NASDAQ:AXGN) has been trending somewhat positive on Monday, Accern Sentiment Analysis reports. The research firm rates the sentiment of media coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. AxoGen earned a media sentiment score of 0.23 on Accern’s scale. Accern also gave news headlines about the medical equipment provider an impact score of 46.0717756912611 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Here are some of the headlines that may have effected Accern’s analysis:
- Brokers Issue Forecasts for AxoGen, Inc.’s FY2018 Earnings (AXGN) (americanbankingnews.com)
- AxoGen, Inc. (AXGN) Receives Consensus Recommendation of “Buy” from Brokerages (americanbankingnews.com)
- Blog Exposure – Boston Scientific Acquired EMcision for Undisclosed Amount (finance.yahoo.com)
- AWM Investment Company Inc. Has $7.97 Million Holdings in AxoGen, Inc. (AXGN) (americanbankingnews.com)
- Are Earnings Prospects Improving For Loss-Making AxoGen Inc’s (NASDAQ:AXGN)? (finance.yahoo.com)
A number of equities analysts recently weighed in on AXGN shares. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of AxoGen in a research note on Friday, January 5th. BidaskClub lowered shares of AxoGen from a “strong-buy” rating to a “buy” rating in a research note on Thursday, January 11th. Jefferies Group started coverage on shares of AxoGen in a research note on Thursday, November 30th. They issued a “buy” rating and a $35.00 target price for the company. Lake Street Capital upped their target price on shares of AxoGen from $22.00 to $26.00 and gave the stock a “buy” rating in a research note on Tuesday, November 21st. Finally, Leerink Swann upped their target price on shares of AxoGen from $26.00 to $30.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 21st. One analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company’s stock. AxoGen presently has an average rating of “Buy” and a consensus price target of $31.71.
AxoGen (NASDAQ:AXGN) last announced its earnings results on Wednesday, February 28th. The medical equipment provider reported ($0.07) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.09) by $0.02. AxoGen had a negative net margin of 17.29% and a negative return on equity of 70.63%. The firm had revenue of $16.97 million during the quarter, compared to analyst estimates of $16.38 million. During the same period in the prior year, the business earned ($0.10) EPS. The company’s revenue for the quarter was up 48.7% compared to the same quarter last year. analysts predict that AxoGen will post -0.28 earnings per share for the current year.
In other news, Director Jamie Mark Grooms sold 38,405 shares of the stock in a transaction dated Tuesday, December 12th. The shares were sold at an average price of $26.35, for a total transaction of $1,011,971.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Over the last 90 days, insiders have sold 207,812 shares of company stock valued at $5,604,984. Company insiders own 9.33% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This news story was originally reported by BBNS and is the sole property of of BBNS. If you are accessing this news story on another domain, it was stolen and republished in violation of US and international trademark & copyright law. The original version of this news story can be accessed at https://baseballnewssource.com/2018/03/12/axogen-axgn-getting-somewhat-favorable-press-coverage-report-shows/2017539.html.
AxoGen, Inc provides surgical solutions for peripheral nerve injuries. The companys surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.
Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.